Cmed Group, Horsham, U.K., has been selected as one of six preferred providers offering its clinical research expertise to a consortium of 14 global health Product Development Partnerships (PDPs). The PDPs are working to develop and deliver affordable treatments and vaccines that will help improve the lives of the some of the world’s most vulnerable people, especially those in developing countries.
Cmed Group is expected to provide the PDPs with a wide range of eClinical technology capabilities, such as electronic data capture (EDC) and data management, and CRO services.
During the next two years, the PDPs are expected to fund more than 100 clinical trials. These Phase I through Phase IV trials will focus on infectious diseases, including HIV, malaria and tuberculosis (TB).
Cmed Technology has been employed by the Aeras, a non-profit PDP research organization developing new TB vaccines and ensuring that they are distributed to all who need them around the world. As part of a Phase II double-blind, randomized clinical trial of a TB vaccine candidate in infants, Aeras used Cmed Technology’s Timaeus on-demand eClinical platform to electronically capture data from three clinical sites in South Africa, while managing and analyzing the data from its U.S. headquarters in Rockville, Md.
“Cmed Group feels privileged to have been selected to help the PDPs with the development of new medicines in Third-World Countries,” said Dr. David Connelly, CEO of Cmed Group. “We hope to provide a full range of clinical services and our Timaeus on-demand eClinical platform to help perform electronic data capture more efficiently and accurately as well as rapidly communicate and manage data across mobile phone networks or satellites in extremely challenging areas with limited or no Internet connectivity. The end result will be highly rewarding—bringing the prospect of better health one step closer for the world’s poor.”
Release Date: April 20, 2011
Source: Cmed Group